Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at biomarkers in urine samples from patients with Wilms tumor.
Other: laboratory biomarker analysis
Other: metabolic assessment
Other: specimen magnetic resonance imaging
|Official Title:||Characterization of Urinary Metabolite Profiles in Wilms Tumor|
- Identification of metabolomic markers in urine that would assist in identifying higher risk of relapse of Wilms tumor in otherwise lower-risk stratified patients as assessed by NMR spectroscopy and PCA [ Designated as safety issue: No ]
|Study Start Date:||June 2012|
|Estimated Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
- To characterize the urinary metabolite signature of 10 stage III, favorable-histology, Wilms tumor patients from the Cooperative Human Tissue Network (CHTN) Databank, as distinct from 10 normal controls.
- To characterize and compare the urinary metabolite profile in 50 randomly selected, stage III, favorable-histology, Wilms tumor patients enriched with an additional 30 stage III Wilms tumor patients who have relapsed.
- To establish if the potential poor outcome (defined as relapse) in the favorable-histology group has a specific metabolite signature.
- To characterize the urinary metabolite signature of Wilms tumor in patients with unfavorable histology (diffuse anaplasia) and compare it to those with favorable histology.
OUTLINE: Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also be examined by NMR and PCA.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01614808
|Principal Investigator:||Dawn Maclellan, MD||IWK Health Centre|